Navigation Links
Prostate cancer survival rates improved since introduction of PSA testing
Date:8/22/2012

Philadelphia, PA, August 23, 2012 The routine use of prostate specific antigen (PSA) testing for screening and monitoring prostate cancer has led to early and more sensitive detection of the disease. A new study published in The Journal of Urology reports that in the "PSA era," survival has improved for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body and the disparity between African American and Caucasian men has been resolved.

"Our analysis indicates an overall improvement in risk adjusted survival rates for non-African American and African American men. Of note is the resolution of disparity in survival between the races found in earlier studies," says lead investigator Ian M. Thompson, Jr., MD, Director of the Cancer Therapy and Research Center, a National Cancer Institute-Designated Cancer Center, and Professor in the Department of Urology at the UT Health Science Center at San Antonio, TX.

The Southwest Oncology Group, a National Cancer Institute (NCI) sponsored organization that conducts clinical trials in adult cancers, has performed a series of clinical trials over the last three decades that evaluated patient survival after androgen deprivation treatment (ADT) for prostate cancer. Two of the trials took place before, and one took place after the introduction of PSA screening. "These sequential trials provide an opportunity to address the question of whether survival has improved since the advent of widespread PSA screening and follow-up testing," says Dr. Thompson. Patient populations and eligibility criteria were comparable across the three studies, which enrolled patients from cancer centers around the country. Patients in all three trials received similar ADT treatments.

Median survival in trial S8494, which enrolled patients from 1985 to 1986, was 30 months, and median survival in trial S8894, which enrolled patients from 1989 to 1994, was 33 months. In contrast, median survival in trial S9346, which enrolled patients from 1995 to 2009, was 49 months. A 30% decreased risk of death was found in the most recent trial (S9346) from the previous trial (S8894).

The interaction of various risk factors, such as extensive versus minimal disease, older age, race, and body mass index was assessed. In S8494 the median survival for African American men was 27 months, while in S9346, the survival rate was 48 months, which is very close to that of white men.

Dr. Thompson notes that African American men had poorer results in the earlier studies despite receiving treatment in a carefully overseen clinical trial. "When we evaluated ZIP code summary information regarding income and education, there was no shift in socioeconomic status over time. We hypothesize that this improvement is based on greater awareness of prostate cancer and improved health seeking behavior in African American men." However, African American men have a two- to three-fold greater incidence of newly diagnosed metastatic prostate cancer compared to white men, which contributes to a similarly increased mortality rate. "A greater effort is needed to eliminate disparities in prostate cancer," he says.

Dr. Thompson concludes, "While not all of these welcome improvements can be attributed strictly to PSA testing, without a doubt it has played a role in extending many lives,"


'/>"/>

Contact: Linda Gruner
jumedia@elsevier.com
212-633-3923
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
4. Study examines adverse effects among different radiation therapies for prostate cancer
5. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
6. Warren Buffett Has Early Stage Prostate Cancer
7. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
8. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
9. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
10. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
11. Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... GROVE, ILL. (PRWEB) , ... January 24, 2017 ... ... odor abatement solutions, announced that it has officially formed a distribution partnership with ... equipment for the industrial odor management industry. , Through the agreement, OMI Industries ...
(Date:1/24/2017)... ... ... This Saturday, January 28, the BCFA presents more than 20 local performances including ... musicians Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide ... at Chinese games, crafts & more. Festivities begin at 11:00 am and end at ...
(Date:1/24/2017)... ... , ... The results from the American Cancer Society’s newest report ... cancer patients: incidents of cancer is down as is the likelihood of prostate cancer ... has dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience for ... Agua is renowned for introducing the world’s first untouched bottled water purposed exclusively ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s ... finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , ... Judith Coats and Dr. David Coats. In September of 1983, they flew to ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... , January 24, 2017 Stock-Callers.com ... Zoetis Inc. (NYSE: ZTS ), Mallinckrodt PLC (NYSE: ... ), and Diplomat Pharmacy Inc. (NYSE: DPLO ). ... for significant change in 2017 for the Generic Drugs industry, ... because of the industry,s current growth, and a speedier FDA ...
(Date:1/24/2017)... -- Laboratory Markets Limited has completed a comprehensive market ... both clinical and research laboratory settings. This study, which ... $6.8 billion and growing to $9.2 billion (CAGR of ... of mass spectrometry across more than 5,200 clinical and ... in the use of mass spectrometry in terms of ...
Breaking Medicine Technology: